Epstein Secrets

ting in September, a late start that=worries the executive director of the state's marketplace. "It's a concern that =e're testing this late," said Tom Betlach, who runs the Arizona Health=Care Cost Containment System. "Usually when you do testing, you have to go ahead and address any changes. Given the Oct

eutical companies that ma=e nearly all the IV solutions used in the United States. It was a rare unguarded c=mment. Ms. Spak — like a spokesman for Hospira, another giant in the fie=d — later insisted that all information about saline solution prices was private. In fact, manufacturers ar= required to

ceutical companies that make nearly all the IV solutions used in the United States. It was a rare unguarded comment. Ms. Spak — like a spokesman for Hospira, another giant in the field — later insisted that all information about saline solution prices was private. In fact, manufacturers are required to r

sting in September, a late start that worries the executive director of the state’s marketplace. “It’s a concern that we’re testing this late,” said Tom Betlach, who runs the Arizona Health Care Cost Containment System. “Usually when you do testing, you have to go ahead and address any changes. Given the Oct

aceutical companies that make nearly all the IV solutions used in the United States. It was a rare unguarded comment. Ms. Spak — like a spokesman for Hospira, another giant in the field — later insisted that all information about saline solution prices was private. In fact, manufacturers are required to re

esting in September, a late start that worries the executive director of the state's marketplace. "It's a concern that we're testing this late," said Tom Betlach, who runs the Arizona Health Care Cost Containment System. "Usually when you do testing, you have to go ahead and address any changes. Given the Octo